|
FDA approves Teva’s injectable Treanda
Globes … (FDA) has approved a new injectable version Treanda for treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and chronic lymphocytic leukemia. |
Why Belgian and Dutch organ donation data are so different – Livemint
LivemintWhy Belgian and Dutch organ donation data are so differentLivemintThe Netherlands got this number of 28% after a very heavy advertising campaign, with millions spent on publicity, public outreach and a soap opera to make people sensitive to don…
First Lady champions mobile blood donation units – Capital FM Kenya
Capital FM Kenya |
First Lady champions mobile blood donation units
Capital FM Kenya Gachoka will take part in the Bank of America Chicago Marathon 2013 to raise funds for purchase of mobile blood donation units in the country. Gachoka’s initiative was sparked by numerous appeals for blood in the media. She decided to participate in … |
Teva's (TEVA) TREANDA Approved by US FDA – StreetInsider.com (subscription)
|
Teva’s (TEVA) TREANDA Approved by US FDA
StreetInsider.com (subscription) TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … |
FDA Approves Teva's TREANDA(R) (bendamustine HCI) Injection, a New Liquid … – MarketWatch
|
FDA Approves Teva’s TREANDA(R) (bendamustine HCI) Injection, a New Liquid …
MarketWatch TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … |
Halozyme Therapeutics, Inc. (HALO): Bullish On Halozyme: Short-Term … – Seeking Alpha
|
Halozyme Therapeutics, Inc. (HALO): Bullish On Halozyme: Short-Term …
Seeking Alpha The second therapy is MabThera SC, or Rituximab, with trade name Rituxan. Rituxan was approved in the US in 1997 for the treatment of non-Hodgkin’s lymphoma. With validation of the approval of the monoclonal antibody Herceptin SC, it’s looking like … |
BCM Researchers Discover Simpler, Improved Biomarkers to Predict Heart … – BioNews Texas
BioNews TexasBCM Researchers Discover Simpler, Improved Biomarkers to Predict Heart …BioNews Texasbiomarkers for heart failure Researchers at the Baylor College of Medicine and the Michael E. DeBakey Veterans Affairs hospital discovered two improved …
Avacta Appoints New R&D Chief For Affimer Antibodies Alternative – London South East
Avacta Appoints New R&D Chief For Affimer Antibodies AlternativeLondon South EastAvacta acquired the intellectual property rights to Affimer – an alternative to the antibodies widely used in life-sciences research, diagnostics and therapeutics – in…
6 Reasons Why There's No Wrong Way to Be a Woman – Huffington Post Canada
|
6 Reasons Why There’s No Wrong Way to Be a Woman
Huffington Post Canada Do you want to live a clean and religious life? Okay. Go for it. Do you want to burn your bras and swing ….. know what I’d do, or the person I would be without her. This pic is typical of us on holiday – our cab driver in India decided that traffic … |
Three MCW Faculty to Receive Distinguished Service Awards – Wauwatosa Now
|
Three MCW Faculty to Receive Distinguished Service Awards
Wauwatosa Now Dr. Franco helped lead program development in Froedtert & the Medical College of Wisconsin’s liver transplant and hepatitis treatment programs. He has served as Director of Hepatology and Medical Director of Liver Transplantation and has participated … |